Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
13 pending office actions • 8 art units • 13 examiners • 0 of 13 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
UNIVERSITEIT ANTWERPEN manages 12 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 12 actions are assigned to 12 distinct examiners, meaning each pending matter is handled by a different individual. Sorie Ibrahim Koroma is the busiest examiner with 1 pending office action. The portfolio is distributed across 7 distinct art units. The 12 distinct examiners for 12 pending office actions create a decentralized prosecution environment. Practitioners must navigate different examiner perspectives across the 7 distinct art units. The 1 pending office action assigned to the busiest examiner confirms that no individual official holds a concentration of the company's active matters.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (8%) |
| §103 only | 2 (15%) |
| §112 only | 5 (38%) |
| Multi-statute (no §101) | 5 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOROMA, SORIE IBRAHIM | 1 | — | — |
| MCKOY, QUINCY ANDRE | 1 | 68.8% | +39.4% |
| JACKSON III, WALTER | 1 | 100.0% | +0.0% |
| RUMP, RICHARD M | 1 | 74.6% | +20.1% |
| TSUI, YUNG-SHENG M | 1 | 66.4% | +6.6% |
| BONAPARTE, AMY C | 1 | 79.3% | +23.2% |
| PATEL, NIKETA I | 1 | 41.1% | +8.3% |
| DOLETSKI, BLAINE G | 1 | 75.0% | +9.1% |
| GRASER, JENNIFER E | 1 | 76.7% | +23.4% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291554 | TOOL FOR CONTINUOUS INSERTION-DEPTH MONITORING FOR IMPLANTABLE LEAD | PATEL, NIKETA I | 38d overdue |
| 18552827 | Vaccine Compositions for Trypanosomatids | GRASER, JENNIFER E | 3d overdue |
| 18690996 | FEEDING SYSTEM FOR FEEDING POWDER MATERIAL AND SYSTEM FOR CONTINUOUS PRODUCTION OF SOLID DOSAGE FORMS | TSUI, YUNG-SHENG M | 75d |
| 18997177 | METHOD AND SYSTEM FOR PROCESSING A PLURALITY OF CAMERA IMAGES OF A HUMAN BODY TARGET AREA OVER TIME | KOROMA, SORIE IBRAHIM | — |
| 18718343 | METHOD FOR OBTAINING A NEUROMUSCULAR ORGANOID AND USE THEREOF | JACKSON III, WALTER | — |
| 18267231 | Cell-Based Therapeutics Targeting CD70 | STONEBRAKER, ALYSSA RAE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552827 | Vaccine Compositions for Trypanosomatids | GRASER, JENNIFER E | 3d overdue |
| 18276532 | QUINAZOLIN-4-ONE AND THIENO[2,3-D]PYRIMIDIN-4-ONE INHIBITORS OF ERBB4 (HER4) FOR USE IN THE TREATMENT OF CANCER | O DELL, DAVID K | 21d |
| 18871130 | DPP9 BINDING COMPOUNDS | MCKOY, QUINCY ANDRE | — |
| 18701078 | AMMONIUM NITRATE PRODUCTION | RUMP, RICHARD M | — |
| 18688192 | Process for the Production of Levulinic Acid and Derivatives Thereof | BONAPARTE, AMY C | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1684 | 1 |
| 3792 | 1 |
| 1645 | 1 |
| 1621 | 1 |
| 1642 | 1 |
| 2881 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18997177 | METHOD AND SYSTEM FOR PROCESSING A PLURALITY OF CAMERA IMAGES OF A HUMAN BODY TARGET AREA OVER TIME | KOROMA, SORIE IBRAHIM | — | §101§103 | Non-Final OA | — | Pending | Jan 20, 2025 |
| 18871130 | DPP9 BINDING COMPOUNDS | MCKOY, QUINCY ANDRE | — | §112 | Non-Final OA | — | Pending | Dec 02, 2024 |
| 18718343 | METHOD FOR OBTAINING A NEUROMUSCULAR ORGANOID AND USE THEREOF | JACKSON III, WALTER | 1638 | §103§112 | Non-Final OA | — | Pending | Jun 10, 2024 |
| 18701078 | AMMONIUM NITRATE PRODUCTION | RUMP, RICHARD M | — | §112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18690996 | FEEDING SYSTEM FOR FEEDING POWDER MATERIAL AND SYSTEM FOR CONTINUOUS PRODUCTION OF SOLID DOSAGE FORMS | TSUI, YUNG-SHENG M | 1684 | §102§112 | Non-Final OA | 75d | Pending | Mar 11, 2024 |
| 18688192 | Process for the Production of Levulinic Acid and Derivatives Thereof | BONAPARTE, AMY C | — | §112 | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18291554 | TOOL FOR CONTINUOUS INSERTION-DEPTH MONITORING FOR IMPLANTABLE LEAD | PATEL, NIKETA I | 3792 | §102§103§112 | Non-Final OA | 38d overdue | Pending | Jan 23, 2024 |
| 18578432 | TWO-STAGE CHEMICAL RECYCLING OF POLYURETHANES | DOLETSKI, BLAINE G | — | §103 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18552827 | Vaccine Compositions for Trypanosomatids | GRASER, JENNIFER E | 1645 | §103§112 | Final Rejection | 3d overdue | Pending | Sep 27, 2023 |
| 18276532 | QUINAZOLIN-4-ONE AND THIENO[2,3-D]PYRIMIDIN-4-ONE INHIBITORS OF ERBB4 (HER4) FOR USE IN THE TREATMENT OF CANCER | O DELL, DAVID K | 1621 | §112 | Non-Final OA | 21d | Pending | Aug 09, 2023 |
| 18267231 | Cell-Based Therapeutics Targeting CD70 | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112 | Non-Final OA | — | Pending | Jun 14, 2023 |
| 18265897 | CHARGED PARTICLE MICROSCOPY MEMS SAMPLE SUPPORT | STOFFA, WYATT A | 2881 | §103 | Final Rejection | 16d overdue | Pending | Jun 07, 2023 |
| 17627953 | MUCIN ISOFORMS IN DISEASES CHARACTERIZED BY BARRIER DYSFUNCTION | BORGEEST, CHRISTINA M | 1675 | §112 | Final Rejection | 13d | Pending | Jan 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial